Where is Tongxin Biotechnology and what does it do?

Wuxi Tongxin Biotechnology Co., Ltd. was founded by returned scholars with a registered capital of 7.5 million, is a high-tech enterprise specializing in the research of food safety residue rapid detection technology. Wuxi Tongxin will cell biology, molecular biology and immunology and other fields of the most advanced scientific research results applied to clinical, dedicated to food safety ELISA rapid test kits and colloidal gold rapid test card research and development, production and sales, the formation of a complete product development, reporting, production system. 2009, the company was named Wuxi "530" class A project; 2010, the company was awarded "530" class A project; 2010, the company was awarded "530" class A project; 2010, the company was awarded "530" class A project. In 2009, the company was awarded as Wuxi City "530 Class A Project"; in 2010, the company built a 100,000 class purified constant temperature and humidity production workshop (800 square meters) and R & D laboratory (600 square meters) with complete instrumentation and equipment configuration in line with the GMP requirements, and passed the acceptance of the Pharmaceutical Supervision and Administration Bureau in July 2010, and obtained the National Medical Device Class III Manufacturing License. The company has built a platform for colloidal rapid immunoassay and enzyme-linked immunosorbent assay. The company also undertook the 2010 Jiangsu Provincial Science and Technology Support Program project and the 2010 Ministry of Science and Technology Small and Medium-sized Enterprise Innovation Fund.

Wuxi Tongxin has established cooperation with 11 provincial animal disease control centers in Jiangsu, Anhui, Hubei and Sichuan provinces. The ELISA diagnostic kit for Brucellosis in cattle and sheep developed with the National Microbiology Reference Laboratory of Huazhong Agricultural University*** has reached the highest level in China, and was in mass production in August 2011.On December 29th, 2010, Wuxi Tongxin signed an agency agreement with Chengdu Biopharmaceuticals, which entrusted Wuxi Tongxin with the production of vaccines and diagnostic kits for animal diseases, and Wuxi Tongxin acted as the agent for Chengdu Biopharmaceuticals in the areas of Suzhou, Zhejiang and Lu, as well as the sales of biological products. Wuxi Tongxin is the agent of Chengdu Biopharmaceuticals in Suzhou, Zhejiang and Lu regions for the sales of biological products, and **** with the research and development of new vaccines. 2010 August, the company's GMP workshop through the Ministry of Health, three types of in vitro diagnostic reagent production license. 2011 January, the company's research and development of human renal transplantation rejection reagent kits to obtain the patent certificate, breaking the monopoly of foreign countries.

The company has a total area of 2,000 square meters, including 600 square meters of R&D laboratory. Among them, 100 square meters of quality inspection room are all built in strict accordance with GMP specification requirements, with cleanliness of 10,000 levels and local 100 levels. The laboratory has independent air-conditioning system, water system, power supply system, independent raw materials and special materials warehouse, and nearly 100 meters of semi-finished products cold storage. The company has three sets of R&D lines for enzyme immunoassay, colloidal gold and chemiluminescence. There are 60 sets of R&D equipments and 20 sets of testing equipments, which can effectively guarantee the quality and system of R&D and meet the requirements of laws and regulations. Tongxin has established a 10,000-level cleanliness of the preparation of human serum and negative-positive standards of the preparation of the workshop, and at the same time established a set of management procedures (SMP) and a set of standard operating procedures (SOP).